OPTIMIZING ADHERENCE TO THERAPY IN HEPATITIS C:
CHALLENGES AND EMERGING STRATEGIES

Supplement 3 to Volume 71, May 2004

SUPPLEMENT EDITOR
ZOBAIR M. YOUNOSSI, MD, MPH
Inova Fairfax Hospital

ASSOCIATE EDITOR
WILLIAM D. CAREY, MD
The Cleveland Clinic

ASSOCIATE EDITOR
ANTHONY S. TAVILL, MD
MetroHealth Medical Center

CONTENTS

Foreword ............................................................................................................................................... S2

The evolving treatment of chronic hepatitis C: Where we stand a decade out ........................................... S3
SHERIF SAADEH, MD, and GARY L. DAVIS, MD

Initial treatment for chronic hepatitis C: Current therapies and their optimal dosing and duration .......... S8
KEYUR PATEL, MD, and JOHN G. McHUTCHISON, MD

Retreatment of patients who do not respond to initial therapy for chronic hepatitis C .......................... S13
MITCHELL L. SHIFFMAN, MD

Managing the hematologic side effects of antiviral therapy for chronic hepatitis C: Anemia, neutropenia, and thrombocytopenia .......................................................... S17
JANUS P. ONG, MD, and ZOBAIR M. YOUNOSSI, MD, MPH

The role of hematopoietic growth factors in special populations with chronic hepatitis C: Patients with HIV coinfection, end-stage renal disease, or liver transplantation .............. S22
STEVAN A. GONZALEZ, MD, and IRA M. JACOBSON, MD

Managing the neuropsychiatric side effects of interferon-based therapy for hepatitis C ...................... S27
CATHERINE C. CRONE, MD; GEOFFREY M. GABRIEL, MD; and THOMAS N. WISE, MD

The role of physician extenders in managing patients with chronic hepatitis C ................................... S33
HARPREET GUJRAL, RN, MSN, CRNP; CARLA VISCOMI, RN, BSN; and ROCHELLE COLLANTES, MD, MPH

This publication is supported by an unrestricted educational grant from Amgen Inc.

Topics and editors for supplements to the Cleveland Clinic Journal of Medicine are determined by the Journal’s editor-in-chief and staff. Supplement editors are chosen for their expertise in the topics discussed and are responsible for the scientific quality of supplements, including the review process. The Journal ensures that supplement editors and authors fully disclose any relationships with industry, including the supplement underwriter. For full guidelines on grant-supported supplements to the Journal, go to www.ccjm.org/pdffiles/guidelines.pdf.

Author financial conflict-of-interest disclosures appear within the authors’ respective articles.

Copyright © 2004 The Cleveland Clinic Foundation.
The statements and opinions expressed in this supplement to the Cleveland Clinic Journal of Medicine are those of the authors and not necessarily of The Cleveland Clinic Foundation, its Board of Trustees, or Amgen Inc.
The Cleveland Clinic Journal of Medicine (ISSN 0891-1150) is published 12 times yearly by The Cleveland Clinic Foundation.
Postmaster address changes: Cleveland Clinic Journal of Medicine, NA32, 9500 Euclid Avenue, Cleveland, OH 44195. Subscription orders, editorial, reprint, and production offices (same address): (216) 444-2663 (phone); (216) 444-9385 (fax); ccjm@ccf.org (e-mail); www.ccjm.org (Web)
Printed in USA.